{"entity":{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","aka":["Miracogen","Shanghai Miracogen Inc.","美雅珂生物"],"tldr":"Shanghai Miracogen is a Chinese antibody-drug conjugate developer whose HER2 conjugate MRG002 has been tested across breast, stomach, bladder and biliary cancers and whose EGFR conjugate MRG003 targets head and neck and nasopharyngeal cancer.","summary":"Shanghai Miracogen builds antibody-drug conjugates with site-specific conjugation and auristatin payloads. MRG002 links a HER2 antibody to monomethyl auristatin E and has been studied in HER2-positive and HER2-low breast cancer, gastric cancer, urothelial carcinoma and biliary tract cancer. MRG003 targets EGFR in nasopharyngeal and head and neck squamous carcinomas, and MRG004A targets tissue factor in pancreatic cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.miracogen.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["mrg002"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.miracogen.com/","founded":2015,"investors":[],"funding":[]},"route":"/companies/shanghai-miracogen/","neighbours":{"drug":[{"id":"mrg002","kind":"drug","name":"MRG002","route":"/drugs/mrg002/"}]}}